Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvador Cabrera

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Revista Medica De Chile|November 9, 2021
[Pharmacokinetic interactions of fruit juices and herbal preparations]Matías Cortés, Rodrigo Díaz, Samuel Verdugo, et al.
Drug Metabolism and Personalized Therapy|January 26, 2020
Dosage of phenytoin in neurocritical patients using Bayesian algorithms: a pilot studyDaniel Muñoz-Pichuante, Lorenzo Villa Zapata, Salvador Cabrera, et al.
AIDS Patient Care and Stds|October 30, 2009
Hyperhidrosis in association with efavirenzAurelio Fuertes, Aurelio Fuertes Martín, Salvador Cabrera, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patientsAlmudena Sánchez, Salvador Cabrera, Dolores Santos, et al.
Personalized Medicine|June 28, 2024
Usefulness of vancomycin treatment individualization via Bayesian algorithms: a 5-year study in critical patientsSalvador Cabrera Figueroa, Diego Salazar Pincheira, Claudio Bustos Navarrete, et al.
Revista Medica Del Instituto Mexicano Del Seguro Social|May 6, 2026
[Cost-effectiveness of the Lose Weight, Gain Life program]Ronald González-Espejel, Rodolfo Rivas-Ruiz, Sergio Carlos Fernández-Martínez, et al.
Pharmacogenomics|July 18, 2013
Impact of pharmacogenetics on CNS side effects related to efavirenzAlmudena Sánchez Martín, Salvador Cabrera Figueroa, Raquel Cruz Guerrero, et al.
Clinical Drug Investigation|May 6, 2010
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIVSalvador Cabrera Figueroa, Alicia Iglesias Gómez, Almudena Sánchez Martín, et al.
Drug Metabolism and Pharmacokinetics|September 27, 2016
Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patientsAlmudena Sánchez-Martín, Salvador Cabrera Figueroa, Raquel Cruz, et al.
Therapeutic Drug Monitoring|September 14, 2011
Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patientsElena López Aspiroz, Dolores Santos Buelga, Salvador Cabrera Figueroa, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Revista Medica De Chile|November 9, 2021
[Pharmacokinetic interactions of fruit juices and herbal preparations]Matías Cortés, Rodrigo Díaz, Samuel Verdugo, et al.
Drug Metabolism and Personalized Therapy|January 26, 2020
Dosage of phenytoin in neurocritical patients using Bayesian algorithms: a pilot studyDaniel Muñoz-Pichuante, Lorenzo Villa Zapata, Salvador Cabrera, et al.
AIDS Patient Care and Stds|October 30, 2009
Hyperhidrosis in association with efavirenzAurelio Fuertes, Aurelio Fuertes Martín, Salvador Cabrera, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patientsAlmudena Sánchez, Salvador Cabrera, Dolores Santos, et al.
Personalized Medicine|June 28, 2024
Usefulness of vancomycin treatment individualization via Bayesian algorithms: a 5-year study in critical patientsSalvador Cabrera Figueroa, Diego Salazar Pincheira, Claudio Bustos Navarrete, et al.
Revista Medica Del Instituto Mexicano Del Seguro Social|May 6, 2026
[Cost-effectiveness of the Lose Weight, Gain Life program]Ronald González-Espejel, Rodolfo Rivas-Ruiz, Sergio Carlos Fernández-Martínez, et al.
Pharmacogenomics|July 18, 2013
Impact of pharmacogenetics on CNS side effects related to efavirenzAlmudena Sánchez Martín, Salvador Cabrera Figueroa, Raquel Cruz Guerrero, et al.
Clinical Drug Investigation|May 6, 2010
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIVSalvador Cabrera Figueroa, Alicia Iglesias Gómez, Almudena Sánchez Martín, et al.
Drug Metabolism and Pharmacokinetics|September 27, 2016
Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patientsAlmudena Sánchez-Martín, Salvador Cabrera Figueroa, Raquel Cruz, et al.
Therapeutic Drug Monitoring|September 14, 2011
Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patientsElena López Aspiroz, Dolores Santos Buelga, Salvador Cabrera Figueroa, et al.
Pageof 2